Protalix reported 2013 highlights Protalix BioTherapeutics reported 2013 highlights. ELELYSO/UPLYSO highlights include: approval in Brazil, Mexico and Chile; in Israel, since the addition of ELELYSO to Israel's national healthcare reimbursement basket in early 2013, ELELYSO has become the drug of choice for na´ve adult Gaucher patients; in Chile, during the Q4 of 2013, all adult Gaucher patients previously treated with other enzyme replacement therapies were successfully switched to UPLYSO/ELELYSO; An application for a pediatric indication of ELELYSO has been submitted to the FDA. The Company also entered into a supply and technology transfer agreement in Brazil for UPLYSO, whereby Fiocruz committed to purchase at least approximately $40M worth of the drug during the first two years of the agreement and at least approximately $40M worth of the drug each subsequent year under the agreement. The first shipment of the drug to Brazil under the agreement with Fiocruz has just been made. The Company reported positive top-line phase I clinical trial results for Oral GCD in Gaucher patients.
News For PLX From The Last 14 Days
Check below for free stories on PLX the last two weeks.